SCULPTRA (injectable poly-L Lactic acid)
Q-Med AB · Decision date Sep 17, 2026
What did the FDA decide?
The FDA record for P030050/S056 lists a 30-day notice with decision OK30, dated 2026-09-17, for SCULPTRA (injectable poly-L lactic acid). The stated purpose is to modify compounding reactors R11 and R12 so they are consistent with reactor systems R11A and R12A. The supplement reason is given as a process change covering manufacturer, sterilizer, packager or supplier.
The filing does not describe how the reactors were changed, how R11A and R12A differ from R11 and R12, or what consistency means in engineering terms, so those details remain unknown. The stated purpose is a manufacturing change; it is not reported evidence of safety or clinical effectiveness. The identifier P030050 links the notice to the original PMA for this device, but a supplement is not an approval of the whole system.
FDA approval order statement
Approval to modify compounding reactors R11 and R12 to be consistent with reactor systems R11A and R12A.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 17, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030050/S056
- Regulatory pathway
- PMA supplement
- Applicant
- Q-Med AB
- Product code
- LMH
- Decision code
- OK30
- Decision date
- Sep 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
For the original device and its historical approval scope, see PMA P030050. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030050 · Original PMA
SCULPTRA AND SCULPTRA AESTHETIC
P030050/S056 received
Application receipt date recorded by FDA.
P030050/S056 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P030050. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030050
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Q-Med AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seminariegatan 21, Uppsala, SE-752-28
Sources and methodology
- Original FDA record: P030050/S056
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




